Invex Therapeutics Ltd. (IXC) AI Stock Analysis

• Market Cap: AU$6.99M
• Dividend Yield: N/A
• Average Volume (3M): 28.99K
• Price to Earnings (P/E): 62.0
• Beta (1Y): 0.05
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): <0.01
• Shares Outstanding: 75,153,850
• 10 Day Avg. Volume: 2,474
• 30 Day Avg. Volume: 28,993
• PEG Ratio: 0.50
• Price to Book (P/B): 1.13
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -16.32
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 57 Neutral
• Price Target: ―

Invex Therapeutics Ltd. shows strong technical momentum, but faces significant financial challenges, particularly with profitability. The stock is trading above key moving averages, yet the high P/E ratio and lack of dividends suggest overvaluation risks. Despite a stable balance sheet, the negative income and cash flow issues weigh on the overall score.

Invex Therapeutics Ltd. Business Overview & Revenue Model

Company Description

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is based in Perth, Australia.

How the Company Makes Money

Invex Therapeutics Ltd. generates revenue through the development and potential commercialization of its pharmaceutical products. The company's primary revenue streams include licensing agreements and strategic partnerships with other pharmaceutical companies for the development and distribution of its pipeline products. Invex may also receive milestone payments and royalties from these collaborations, contingent upon the successful development and commercialization milestones. Additionally, the company might pursue government grants or funding from research institutions to support its R&D activities. As Invex progresses through clinical trials and moves closer to product approval and market entry, it aims to establish sustainable revenue channels through product sales and expanded partnerships.

Invex Therapeutics Ltd. Financial Statement Overview

Summary

Invex Therapeutics Ltd. is in a development phase with growing revenues but still faces significant challenges in achieving profitability. The balance sheet is strong with zero debt, but ongoing losses impact overall financial health. Cash flow management is improving, but negative net income continues to weigh heavily on cash positions.

Income Statement

Invex Therapeutics Ltd. has shown improvements in revenue generation, with a significant increase in total revenue from 2022 to 2023. However, the company is still operating at a loss, as indicated by negative net income and EBIT margins. The gross profit margin is strong at 100%, but the net profit margin is negative due to high operating expenses.

Balance Sheet

The company maintains a strong equity position with no debt, resulting in a commendable debt-to-equity ratio of 0. The equity ratio remains high, indicating stability. However, the return on equity is negative due to ongoing net losses, which is a concern for profitability.

Cash Flow

The cash flow statements show a reduction in free cash flow losses, which suggests improving operational efficiency. Nonetheless, the operating cash flow to net income ratio remains negative, indicating that net income losses are affecting cash flow. The absence of capital expenditures is a positive in maintaining cash reserves.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
1.21M	1.21M	459.08K	182.25K	0.00	0.00
	Gross Profit
1.21M	1.21M	459.08K	182.25K	0.00	0.00
	EBIT
-116.47K	-2.13M	-8.55M	-4.03M	-2.44M	-3.29M
	EBITDA
-741.37K	-720.44K	0.00	0.00	0.00	0.00
	Net Income Common Stockholders
114.36K	-1.64M	-7.75M	-3.95M	-2.28M	-3.36M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.15M	6.03M	22.47M	29.34M	32.72M	26.30M
	Total Assets
6.28M	6.12M	22.80M	29.49M	32.74M	26.42M
	Total Debt
0.00	0.00	0.00	0.00	0.00	0.00
	Net Debt
-6.15M	-6.03M	-22.47M	-29.34M	-32.72M	-26.30M
	Total Liabilities
984.57K	431.63K	1.57M	1.00M	658.61K	2.02M
	Stockholders Equity
5.30M	5.69M	21.23M	28.48M	32.08M	24.40M
Cash Flow		Free Cash Flow
-368.36K	-2.44M	-6.87M	-3.38M	-1.68M	-1.60M
	Operating Cash Flow
-368.36K	-2.44M	-6.87M	-3.38M	-1.68M	-1.60M
	Investing Cash Flow
0.00	0.00	0.00	0.00	0.00	0.00
	Financing Cash Flow
0.00	-14.00M	0.00	0.00	8.09M	15.73M

Invex Therapeutics Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.09
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IXC, the sentiment is Positive. The current price of 0.09 is below the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.08, and above the 200-day MA of 0.08, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 56.97 is Neutral, neither overbought nor oversold. The STOCH value of -50.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IXC.

Invex Therapeutics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IXC	57 Neutral	AU$6.99M	62.00	2.14%	―	―	―
Sector *	54 Neutral	$5.31B	3.26	-45.10%	2.79%	16.76%	0.02%
BITRF		$2.16M	―	-119.28%	―	―	―
NNCSF		$850.15M	75.42	9.23%	―	―	―
A1N		$3.71M	―	-67.69%	―	―	―
RAC	54 Neutral	AU$205.88M	―	-37.20%	―	―	32.02%
AGH	45 Neutral	AU$21.39M	―	-218.38%	―	-14.30%	29.69%

Invex Therapeutics Ltd. Corporate Events

Invex Therapeutics Expands Alzheimer’s Research Collaboration and Reports Financial Stability

Invex Therapeutics Ltd announced an expansion of its research collaboration with Tessara Therapeutics to further investigate the effects of Exenatide on Alzheimer’s Disease models, aiming to gain insights into its potential benefits on neural networks and gene expression. The company also reported prudent cash management with a closing balance of $5.7 million and highlighted a UK R&D tax incentive receipt, while continuing to explore additional asset opportunities.

Invex Therapeutics Updates Registered Office Address

Invex Therapeutics Ltd announced a change of its registered office address, now located at Level 5, 191 St Georges Terrace, Perth WA 6000. This relocation is part of compliance with ASX Listing Rule 3.14, and all other contact information remains unchanged. The announcement reflects ongoing organizational adjustments, which could have implications for its operational efficiencies and stakeholder communications.

Invex Therapeutics Reports Reduced Losses but Withholds Dividends

Invex Therapeutics Ltd reported a significant decrease in other income and a substantial reduction in net loss for the half-year ending December 31, 2024, compared to the previous year. Despite the financial improvements, the company has not declared any dividends for the period, indicating a cautious approach in maintaining financial stability and potentially reinvesting in its operations.